Literature DB >> 2110685

Experimental models of hepatic fibrosis: a review.

H Tsukamoto1, M Matsuoka, S W French.   

Abstract

No experimental model reproduces exactly human liver fibrosis by etiology. Nonetheless, each of the models reviewed in this article has served to enhance our understanding of pathogenetic mechanisms of liver fibrosis. There have been important common findings derived from several different models. The best example is the role of Ito cells in liver fibrogenesis. Involvement of Ito cells was consistently seen in the experimental models regardless of whether the fibrogenic stimulus was nutritional, hepatotoxic, or immunologic. Cellular and molecular mechanisms of Ito cell activation have begun to be explored in different models. Another example is the role of TGF beta in liver fibrogenesis. In both murine schistosomiasis model and Tsukamoto-French rat model, TGF beta was shown to be closely associated with fibrogenesis. With both in vitro and in vivo experimental approaches using cellular and molecular techniques, the experimental model of liver fibrosis will continue to provide data on the pathogenetic mechanisms of liver fibrogenesis. Future genetic and molecular approaches may allow development animal models with liver fibrosis that is inducible and genetically similarity to that of man.

Entities:  

Mesh:

Year:  1990        PMID: 2110685     DOI: 10.1055/s-2008-1040457

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  73 in total

Review 1.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 2.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

3.  Contribution to the study of septal fibrosis of the liver.

Authors:  Z A Andrade
Journal:  Int J Exp Pathol       Date:  1991-10       Impact factor: 1.925

4.  Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis.

Authors:  Q H Nie; Y Q Cheng; Y M Xie; Y X Zhou; Y Z Cao
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

Review 5.  Recent advances in the pathogenesis and diagnosis of liver fibrosis.

Authors:  Natalie J Török
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

6.  Lymph vessel expansion and function in the development of hepatic fibrosis and cirrhosis.

Authors:  B Vollmar; B Wolf; S Siegmund; A D Katsen; M D Menger
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

7.  Eicosanoid production in experimental alcoholic liver disease is related to vitamin E levels and lipid peroxidation.

Authors:  A A Nanji; S Khwaja; S M Sadrzadeh
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

8.  Inhibition on the production of collagen type I, III of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid.

Authors:  Wen-Bin Liu; Chang-Qing Yang; Wei Jiang; Yi-Qing Wang; Jing-Sheng Guo; Bo-Ming He; Ji-Yao Wang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury.

Authors:  Soo Young Park; Hye Won Shin; Kyoung Bun Lee; Min-Jae Lee; Ja-June Jang
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

10.  Activation of protein serine/threonine phosphatase PP2Cα efficiently prevents liver fibrosis.

Authors:  Lirui Wang; Xu Wang; Jing Chen; Zhengyi Yang; Liang Yu; Lihong Hu; Xu Shen
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.